Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19782337 | 0.79 | MEN1 (0.46) | ALDH1A1LMNASMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL24624723 | 0.76 | SMN1; SMN2 (0.32) | SMN1; SMN2KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21189946 | 0.73 | LMNA (0.40) | POLBGAAALDH1A1LMNAKMT2A | |
| SCHEMBL16315594 | 0.68 | CNR1 (0.43) | GAAALDH1A1LMNAHPGD | |
| SCHEMBL13502947 | 0.67 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL12831420 | 0.67 | FAAH (0.41) | POLBALDH1A1LMNATHRBSMN1; SMN2 | |
| SCHEMBL11129304 | 0.67 | TSHR (0.35) | ALDH1A1CYP2C19 | |
| SCHEMBL1774798 | 0.67 | GABRP (0.39) | ALDH1A1LMNAL3MBTL1CYP1A2 | |
| SCHEMBL8379954 | 0.67 | ALDH1A1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL26707065 | 0.66 | MEN1 (0.43) | GAAALDH1A1SMN1; SMN2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293701-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ARGORNA PHARMACEUTICALS CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293701-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ASGR1, HAVCR2, SLC10A1 | POLB 3376/4885GAA 167/4885ALDH1A1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.